SGLT2 Inhibitors in T2D Linked to Lower GI Cancer Risk SGLT2 Inhibitors in T2D Linked to Lower GI Cancer Risk

Researchers used a large national database to compare risk of all types of GI cancers associated with popular drug classes used to treat type 2 diabetes.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Gastroenterology News Source Type: news